ClinicalTrials.gg
Active, not recruitingNCT03748641MAGNITUDEUpdated Nov 3, 2026Results posted

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

A Phase 3 interventional study of Niraparib and Abiraterone Acetate in Castration-Resistant Prostatic Cancer, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 318 sites in 29 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Updated Sep 25, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
765
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Prostatic Neoplasms, Castration-Resistant by Johnson & Johnson — 3 open to participants now, 6 under way, 3 of them phase 3. Prostatic Neoplasms, Castration-Resistant · Johnson & Johnson.

Enrollment
3rd of 10
765 · median 77
Started
2019
the only one that year
Phase 3
3 of 10
2 open now
Registered
7th of 10
by date

Among the 10 studies in Prostatic Neoplasms, Castration-Resistant by Johnson & Johnson, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 3 in phase 3, and was the 7th registered.

Prostatic Neoplasms, Castration-Resistant

85 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 28 are open to participants now.

Browse Prostatic Neoplasms, Castration-Resistant studies →

Open to participants now

3 of the 10 studies in Prostatic Neoplasms, Castration-Resistant by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 25 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (88%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Prostatic Neoplasms, Castration-Resistant by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP and placebo.

03

Conditions studied

  • Castration-Resistant Prostatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • HRR gene alteration (as identified by the sponsor's required assays) as follows:

    1. Cohort 1: positive for HRR gene alteration
    2. Cohort 2: not positive for DRD (that is, HRR gene alteration)
    3. Cohort 3: eligible by HRR status
  • disease documented by positive bone scan or metastatic lesions on computed tomography (CT) or magnetic resonance imaging (MRI)
  • Metastatic prostate cancer in the setting of castrate levels of testosterone less than or equal to (\<=) 50 nanogram per deciliter (ng/dL) on a gonadotropin releasing hormone analog (GnRHa) or bilateral orchiectomy
  • Able to continue GnRHa during the study if not surgically castrate
  • Score of \<= 3 on the brief pain inventory-short form (BPI-SF) question number 3 (worst pain in last 24 hours)

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor
  • Systemic therapy (that is, novel second-generation AR-targeted therapy such as enzalutamide, apalutamide, or darolutamide; taxane-based chemotherapy, or more than 4 months of abiraterone acetate plus prednisone [AAP] prior to randomization) in the castration-resistant prostate cancer (mCRPC) setting; or AAP outside of the mCRPC setting
  • Symptomatic
  • History or current diagnosis of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
  • Other prior (exceptions: adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission) \<= 2 years prior to randomization, or malignancy that currently requires active systemic therapy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
765 participants (actual)

Study arms

  • Experimental
    Cohort 1: Participants with mCRPC and HRR Gene Alteration

    Participants with L1 metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alteration will receive combination of niraparib 200 milligrams (mg) or matching placebo and abiraterone acetate (AA) 1000 mg plus prednisone 10 mg. In the open label extension (OLE) phase participants earlier receiving the combination of niraparib and AAP may continue to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg and those receiving placebo and AAP may cross over depending on the outcome of study to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg.

    Drug: Niraparib · Drug: Abiraterone Acetate · Drug: Prednisone · Drug: Placebo

  • Experimental
    Cohort 2: Participants with mCRPC and No HRR Gene Alteration

    Participants with L1 mCRPC and no HRR Gene alteration will receive combination of niraparib 200 mg or matching placebo and AA 1000 mg plus prednisone 10 mg. In the OLE phase participants earlier receiving the combination of niraparib and AAP may continue to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg and those receiving placebo and AAP may cross over depending on the outcome of study to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg.

    Drug: Niraparib · Drug: Abiraterone Acetate · Drug: Prednisone · Drug: Placebo

  • Experimental
    Cohort 3 (Open-label): Participants with mCRPC

    Participants with mCRPC will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets plus prednisone 10 mg.

    Drug: Prednisone · Drug: New Formulation of Niraparib and Abiraterone Acetate (AA)

Interventions

  • Participants will receive niraparib 200 mg capsules or tablets once daily.

    Also known as: JNJ-64091742

  • Participants will receive AA 1000 mg tablets once daily.

  • Participants will receive prednisone 10 mg tablets daily.

  • DrugPlacebo

    Participants will receive matching placebo once daily.

  • DrugNew Formulation of Niraparib and Abiraterone Acetate (AA)

    Participants will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets once daily.

06

What researchers measure

Primary outcomes

  1. Cohort 1: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)

    As per BICR, rPFS is time interval from the date of randomization to radiographic progression or death, whichever occurred first. Radiographic progression was determined by: (1) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI) as per response evaluation criteria in solid tumors (RECIST) 1.1; (2) Progression of bone lesions observed by bone scan based on prostate cancer working group 3 (PCWG3) criteria. PCWG3 criteria: bone progression was confirmed by subsequent scan greater than or equal to (\>=) 6 weeks later. Week 8 scan was baseline to which all subsequent scans were compared to determine progression. Confirmatory scan \>=2 new lesions indicate progression; scan does not show \>=2 new lesions means no progression. If Week 8 scan less than (\<) 2 new bone lesions compared to baseline, the initial scan \>=2 new lesions compared to Week 8 scan indicates progression if confirmed by subsequent scan \>=6 weeks later.

    Time frame: Up to 32 months

  2. Cohort 1 Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)

    As per BICR, rPFS is time interval from the date of randomization to radiographic progression or death, whichever occurred first. Radiographic progression was determined by: (1) progression of soft tissue lesions measured by CT or MRI as per RECIST 1.1; (2) Progression of bone lesions observed by bone scan based on PCWG3 criteria. PCWG3 criteria: bone progression was confirmed by subsequent scan \>=6 weeks later. Week 8 scan was baseline to which all subsequent scans were compared to determine progression. Confirmatory scan \>=2 new lesions indicate progression; scan does not show \>=2 new lesions means no progression. If Week 8 scan \<2 new bone lesions compared to baseline, the initial scan \>=2 new lesions compared to Week 8 scan indicates progression if confirmed by subsequent scan \>=6 weeks later.

    Time frame: Up to 32 months

Secondary outcomes

  1. Cohort 1: Overall Survival (OS)

    Time frame: Up to 97 months

  2. Cohort 1: Time to Symptomatic Progression

    Time frame: Up to 97 months

  3. Cohort 1: Time to Initiation of Cytotoxic Chemotherapy

    Time frame: Up to 97 months

  4. Observed Plasma Concentrations of Niraparib

    Time frame: Up to 97 months

  5. Observed Plasma Concentrations of Abiraterone

    Time frame: Up to 97 months

  6. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to 96 months

  7. Number of Participants With Treatment-Emergent Adverse Events by Severity

    Time frame: Up to 96 months

  8. Number of Participants With Abnormalities in Laboratory Values

    Time frame: Up to 96 months

07

Results

Posted Oct 4, 2023

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 2: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 2: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 3: Niraparib 200 mg and Abiraterone Acetate 1000 mg FDC + Prednisone 10 mg
Started21221112312495
Breast cancer gene (brca) subgroup1131120052
Completed00000
Not completed21221112312495
Withdrew: Ongoing155148667984
Withdrew: Death545951429
Withdrew: Lost to follow-up02100
Withdrew: Withdrawal by subject32532

Outcome measures

PrimaryCohort 1: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)

As per BICR, rPFS is time interval from the date of randomization to radiographic progression or death, whichever occurred first. Radiographic progression was determined by: (1) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI) as per response evaluation criteria in solid tumors (RECIST) 1.1; (2) Progression of bone lesions observed by bone scan based on prostate cancer working group 3 (PCWG3) criteria. PCWG3 criteria: bone progression was confirmed by subsequent scan greater than or equal to (\>=) 6 weeks later. Week 8 scan was baseline to which all subsequent scans were compared to determine progression. Confirmatory scan \>=2 new lesions indicate progression; scan does not show \>=2 new lesions means no progression. If Week 8 scan less than (\<) 2 new bone lesions compared to baseline, the initial scan \>=2 new lesions compared to Week 8 scan indicates progression if confirmed by subsequent scan \>=6 weeks later.

Time frame:
Up to 32 months
Reported as:
Median · Months
Cohort 1: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)
MonthsCohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg
Cohort 1: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)16.46 (13.83 to 19.38)13.70 (10.91 to 16.39)
Statistical analysis
  • Cohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg vs Cohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg · Log Rank · p = 0.0217 · Hazard ratio (hr): 0.729 · 95% CI 0.556 to 0.956
PrimaryCohort 1 Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)

As per BICR, rPFS is time interval from the date of randomization to radiographic progression or death, whichever occurred first. Radiographic progression was determined by: (1) progression of soft tissue lesions measured by CT or MRI as per RECIST 1.1; (2) Progression of bone lesions observed by bone scan based on PCWG3 criteria. PCWG3 criteria: bone progression was confirmed by subsequent scan \>=6 weeks later. Week 8 scan was baseline to which all subsequent scans were compared to determine progression. Confirmatory scan \>=2 new lesions indicate progression; scan does not show \>=2 new lesions means no progression. If Week 8 scan \<2 new bone lesions compared to baseline, the initial scan \>=2 new lesions compared to Week 8 scan indicates progression if confirmed by subsequent scan \>=6 weeks later.

Time frame:
Up to 32 months
Reported as:
Median · Months
Cohort 1 Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)
MonthsCohort 1 BRCA Subgroup: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 1 BRCA Subgroup: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg
Cohort 1 Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)16.56 (13.86 to NA)10.87 (8.31 to 13.80)
Statistical analysis
  • Cohort 1 BRCA Subgroup: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg vs Cohort 1 BRCA Subgroup: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg · Log Rank · p = 0.0014 · Hazard ratio (hr): 0.533 · 95% CI 0.361 to 0.789
SecondaryCohort 1: Overall Survival (OS)
Time frame:
Up to 97 months

Results for this outcome have not been posted.

SecondaryCohort 1: Time to Symptomatic Progression
Time frame:
Up to 97 months

Results for this outcome have not been posted.

SecondaryCohort 1: Time to Initiation of Cytotoxic Chemotherapy
Time frame:
Up to 97 months

Results for this outcome have not been posted.

SecondaryObserved Plasma Concentrations of Niraparib
Time frame:
Up to 97 months

Results for this outcome have not been posted.

SecondaryObserved Plasma Concentrations of Abiraterone
Time frame:
Up to 97 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time frame:
Up to 96 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment-Emergent Adverse Events by Severity
Time frame:
Up to 96 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Abnormalities in Laboratory Values
Time frame:
Up to 96 months

Results for this outcome have not been posted.

Adverse events

Collected over Up to 32 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg55/212 (25.9%)76/212 (35.8%)198/212 (93.4%)
Cohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg59/211 (28%)52/211 (24.6%)178/211 (84.4%)
Cohort 2: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg53/123 (43.1%)66/123 (53.7%)117/123 (95.1%)
Cohort 2: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg44/123 (35.8%)45/123 (36.6%)108/123 (87.8%)
Cohort 3: Niraparib 200 mg and Abiraterone Acetate 1000 mg FDC + Prednisone 10 mg9/95 (9.5%)21/95 (22.1%)83/95 (87.4%)
Most frequent serious events
Showing 10 of 194
Most frequent serious events
EventCohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 2: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 2: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 3: Niraparib 200 mg and Abiraterone Acetate 1000 mg FDC + Prednisone 10 mg
AnaemiaBlood and lymphatic system disorders12/2122/21120/1232/1232/95
PneumoniaInfections and infestations7/2124/2114/1232/1232/95
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders4/2121/2113/1232/1233/95
Covid-19Infections and infestations6/2121/2113/1230/1230/95
Cardiac FailureCardiac disorders1/2121/2113/1230/1230/95
VomitingGastrointestinal disorders0/2120/2113/1230/1230/95
SepsisInfections and infestations0/2120/2110/1233/1230/95
Acute Kidney InjuryRenal and urinary disorders1/2122/2113/1231/1231/95
Urinary RetentionRenal and urinary disorders4/2122/2110/1233/1230/95
Urinary Tract InfectionInfections and infestations2/2122/2112/1231/1232/95
Most frequent other events
Showing 10 of 45
Most frequent other events
EventCohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 2: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 2: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 3: Niraparib 200 mg and Abiraterone Acetate 1000 mg FDC + Prednisone 10 mg
AnaemiaBlood and lymphatic system disorders95/21243/21159/12319/12337/95
HypertensionVascular disorders66/21244/21141/12327/12315/95
ConstipationGastrointestinal disorders65/21229/21138/12325/12323/95
FatigueGeneral disorders56/21235/21129/12321/12316/95
NauseaGastrointestinal disorders50/21229/21129/12320/12325/95
Decreased AppetiteMetabolism and nutrition disorders30/21213/21129/12311/12313/95
ThrombocytopeniaBlood and lymphatic system disorders45/21218/21124/1233/12311/95
Back PainMusculoskeletal and connective tissue disorders31/21244/21119/12325/1237/95
AstheniaGeneral disorders33/21219/21122/12314/12312/95
NeutropeniaBlood and lymphatic system disorders28/21212/21121/1236/1237/95

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 2: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 2: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 3: Niraparib 200 mg and Abiraterone Acetate 1000 mg FDC + Prednisone 10 mgTotal
Mean69.2 ± 8.7968.6 ± 8.1771.2 ± 7.1171.1 ± 7.5269.2 ± 8.9969.7 ± 8.25
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 2: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 2: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 3: Niraparib 200 mg and Abiraterone Acetate 1000 mg FDC + Prednisone 10 mgTotal
Female000000
Male21221112312495765
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 2: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 2: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 3: Niraparib 200 mg and Abiraterone Acetate 1000 mg FDC + Prednisone 10 mgTotal
Hispanic or Latino26258121283
Not Hispanic or Latino16616911010577627
Unknown or Not Reported201757655
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 2: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 2: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 3: Niraparib 200 mg and Abiraterone Acetate 1000 mg FDC + Prednisone 10 mgTotal
American Indian or Alaska Native110013
Asian2941453714166
Native Hawaiian or Other Pacific Islander001001
Black or African American500038
White160153728370538
More than one race000000
Unknown or Not Reported171654749
Region of Enrollment
Region of Enrollment(Participants)Cohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 2: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 2: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mgCohort 3: Niraparib 200 mg and Abiraterone Acetate 1000 mg FDC + Prednisone 10 mgTotal
ARGENTINA2527218
AUSTRALIA1512129351
BELGIUM5123011
BRAZIL2014001044
BULGARIA100001
CANADA4714319
CHINA7400011
CZECH REPUBLIC4312111
FRANCE131254337
GERMANY040059
HUNGARY7432117
ISRAEL000033
ITALY910331136
MALAYSIA510177140
MEXICO320005
NETHERLANDS3422011
POLAND12121115454
PORTUGAL110035
RUSSIAN FEDERATION192161350
SOUTH KOREA82221171078
SPAIN129912345
SWEDEN421119
TAIWAN84712334
TURKEY181666551
UKRAINE18201211970
UNITED KINGDOM210339
UNITED STATES121123836
08

Study locations

318 sites

Showing the first 100 of 318 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ye D, Saad M, Lee JY, Jung W, Pang ST, Li L, Gurney H, Attard G, Chi KN, Mundle S, Zhuo J, Singh A, Lin Y, Sandhu S. Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study. Int J Urol. 2026 Apr;33(4):e70455. doi: 10.1111/iju.70455. PubMed 42015879 ↗
  • Russu A, Hazra A, Tian H, Haddish-Berhane N, Perez Ruixo JJ, Boulton M. Population Pharmacokinetics of Niraparib/Abiraterone Acetate Administered as Single-Agent Combination and Dual-Acting Tablets Plus Prednisone for Metastatic Castration-Resistant Prostate Cancer. Adv Ther. 2025 Apr;42(4):1860-1880. doi: 10.1007/s12325-025-03104-y. Epub 2025 Feb 28. PubMed 40016438 ↗
  • Rathkopf DE, Roubaud G, Chi KN, Efstathiou E, Attard G, Olmos D, Small EJ, Saad M, Castro E, Kim W, Wu D, Bertzos K, Dibaj S, Zhang J, Francis P, Smith MR. Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial. Eur Urol. 2025 Oct;88(4):359-369. doi: 10.1016/j.eururo.2024.09.003. Epub 2024 Sep 23. PubMed 39317633 ↗
  • Roubaud G, Attard G, Boegemann M, Olmos D, Trevisan M, Antoni L, Pascoe K, Capone C, Van Sanden S, Hashim M, Palmer S, Chi K. Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer. Eur J Cancer. 2024 Sep;209:114183. doi: 10.1016/j.ejca.2024.114183. Epub 2024 Jun 17. PubMed 39111209 ↗
  • De Santis M, Breijo SM, Robinson P, Capone C, Pascoe K, Van Sanden S, Hashim M, Trevisan M, Daly C, Reitsma F, van Beekhuizen S, Ruan H, Heeg B, Verzoni E. Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer. Adv Ther. 2024 Aug;41(8):3039-3058. doi: 10.1007/s12325-024-02918-6. Epub 2024 Jul 3. PubMed 38958846 ↗
  • Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S; MAGNITUDE Principal Investigators. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 Jun 20;41(18):3339-3351. doi: 10.1200/JCO.22.01649. Epub 2023 Mar 23. PubMed 36952634 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Oct 2021, 32 months.

Results were first posted in Oct 2023, 1 year 11 months after primary completion. A results delay was requested in Oct 2022.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2018
First posted
Nov 21, 2018
StartActual
Jan 25, 2019
Primary completionActual
Oct 8, 2021
CompletionEst.
Dec 31, 2027
Results delay requested
Oct 6, 2022
Results first posted
Oct 4, 2023
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia · Santo André, Brazil
Show 1 removed
  • Cepes - Fmabc · São Paulo, Brazil
Sep 25, 2026
Show all 2 updates
  1. Nov 3, 2026
    Minor edits only
    + 2 other changes: verification date and site details
  2. Sep 25, 2026
    1 site added, 1 site removed
    Show site
    • CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia · Santo André, Brazil
    Show 1 removed
    • Cepes - Fmabc · São Paulo, Brazil
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03748641
Responsible party
Sponsor
First posted
Nov 21, 2018
Start date
Jan 25, 2019
Primary completion
Oct 8, 2021
Completion
Dec 31, 2027 (estimated)
Results posted
Oct 4, 2023
Last update
Nov 3, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Niraparib · Abiraterone Acetate

Start the discussion